Smith & Nephew plc
NYSE:SNNMedical - Devices
-$0.43 today
- Market cap
- $12.72B
- Beta
- 0.67
- P/E (TTM)
- 20.1
- EPS (TTM)
- $0.74
- Dividend yield
- 2.59%
Volume 1.22M
Average 1.10M
SNN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Smith & Nephew plcNYSE: SNN
Research & Development · Q4 FY2025 · quarter ended Dec 2025
Research & development declines year over year
Q4 FY2025 research & development of $203M fell 1.5% year over year. Over 3 fiscal years it compounded at +0.1% a year.
Context
- Research & development amounted to 5.6% of revenue in FY2025, down 0.3 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 346M USD
- Year-over-year change
- +0.9%
- 4-year CAGR
- -0.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 346M | +0.9% |
| FY2024 | 2024-12-31 | 343M | +1.2% |
| FY2023 | 2023-12-31 | 339M | -1.7% |
| FY2022 | 2022-12-31 | 345M | -3.1% |
| FY2021 | 2021-12-31 | 356M | — |
Research & Development vs competitors
How SNN compares with its peers on the latest reported figures
- SNN's FY2025 research & development of $346M is the 3rd highest of the 11 companies compared; the peer median is $87.5M.
- Its year-over-year change of +0.9% is the 5th highest of 11, against a peer median of -1.4%.
- Research & development amounts to 5.6% of revenue for SNN, versus a peer median of 5.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.66B | +10.1% | +8.8% | 6.4% | |
| LTM Jun 2026 | $442.9M | -0.2% | +4.1% | 5.2% | |
| FY2025 | $346M | +0.9% | +0.1% | 5.6% | |
| LTM Jun 2026 | $184.82M | +30.3% | +36.3% | 5.9% | |
| LTM Apr 2026 | $123.34M | +27.9% | +25.5% | 5.4% | |
| LTM Mar 2026 | $97.75M | -13.6% | -0.7% | 5.9% | |
| LTM Mar 2026 | $77.25M | -2.6% | +20.1% | 9.8% | |
| LTM Mar 2026 | $61.4M | -16.9% | +5.2% | 7.4% | |
| LTM Mar 2026 | $59.27M | +10.2% | +5.8% | 4.3% | |
| LTM Mar 2026 | $8.98M | -13.5% | +2.5% | 3.7% | |
| LTM Mar 2026 | $2.09M | -9.0% | +31.9% | 1.7% | |
| Peer median (excluding SNN) | $87.5M | -1.4% | +7.3% | 5.6% | |
Competitors are the stored peer set for SNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.21B | 5.22B | 5.55B | 5.81B | 6.16B |
| Cost of Revenue | 1.51B | 1.52B | 1.65B | 1.73B | 1.96B |
| Gross Profit | 3.7B | 3.7B | 3.9B | 4.08B | 4.21B |
| Gross Margin | 71.0% | 70.9% | 70.2% | 70.2% | 68.3% |
| Research & Development | 356M | 345M | 339M | 343M | 346M |
| Selling, General & Admin | 2.64B | 2.71B | 2.83B | 2.9B | 3.04B |
| Operating Expenses | 3.11B | 3.25B | 3.47B | 3.42B | 3.41B |
| Depreciation & Amortization | 507M | 492M | 473M | 449M | 459M |
| EBITDA | 1.22B | 1.15B | 1.21B | 1.34B | 1.34B |
| EBITDA Margin | 23.4% | 22.1% | 21.9% | 23.0% | 21.7% |
| Operating Income | 593M | 450M | 425M | 657M | 794M |
| Operating Margin | 11.4% | 8.6% | 7.7% | 11.3% | 12.9% |
| Interest Income | 6M | 13.99M | 34.13M | 24.01M | 28.07M |
| Interest Expense | 79.99M | 79.95M | 132.51M | 150.06M | 141.33M |
| Other Income / Expenses | (7M) | (215M) | (135M) | (159M) | (15M) |
| Income Before Tax | 586M | 235M | 290M | 498M | 779M |
| Pre-Tax Margin | 11.2% | 4.5% | 5.2% | 8.6% | 12.6% |
| Income Tax Expense | 62M | 12M | 27M | 86M | 154M |
| Net Income | 524M | 223M | 263M | 412M | 625M |
| Net Margin | 10.1% | 4.3% | 4.7% | 7.1% | 10.1% |
| EPS (Basic) | 1.20 | 0.50 | 1.20 | 0.94 | 1.46 |
| EPS (Diluted) | 1.20 | 0.50 | 1.20 | 0.94 | 1.44 |
| Weighted Avg Shares | 438.5M | 437.55M | 217.75M | 438.3M | 433.42M |
| Weighted Avg Shares (Diluted) | 438.86M | 437.55M | 218.44M | 438.3M | 436.47M |
Smith & Nephew plc
NYSE:SNN
Intrinsic Alpha fair value
Locked
Current Price
$30.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.